Short communication: T cell activation in HIV-1/Herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir

AIDS Research and Human Retroviruses

Volumn 29, Issue 1, 2013, Pages 94-98

  Roxby, Alison C ^a   Liu, Amy Y ^a   Drake, Alison L ^a   Kiarie, James N ^b   Richardson, Barbra ^a,c   Lohman Payne, Barbara L ^a,b   John Stewart, Grace C ^a,d   Wald, Anna ^a,c   De Rosa, Stephen ^a,c   Farquhar, Carey ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; PLACEBO; RNA; VALACICLOVIR;

ADULT; ARTICLE; BREAST FEEDING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MIXED INFECTION; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; COINFECTION; DOUBLE-BLIND METHOD; FEMALE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LYMPHOCYTE ACTIVATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SIMPLEXVIRUS; T-LYMPHOCYTES; VALINE; YOUNG ADULT;

EID: 84871851990     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0071     Document Type: Article

References (22)

1. Sheth PM, Sunderji S, Shin LY, et al.: Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 2008;197(10):1394-1401.
2. Ouedraogo A, Nagot N, Vergne L, et al.: Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: A randomized controlled trial. AIDS 2006;20(18):2305-2313.
3. Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356(8):790-799.
4. Lingappa JR, Baeten JM, Wald A, et al.: Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: A randomised placebo- controlled trial. Lancet 2010;375(9717):824-833.
5. Lawn SD, Butera ST, and Folks TM: Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001;14(4):753-777.
6. Clerici M, Butto S, Lukwiya M, et al.: Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000;14(14):2083-2092.
7. Hunt PW, Cao HL, Muzoora C, et al.: Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIVinfected Ugandans initiating antiretroviral therapy. AIDS 2011;25(17):2123-2131.
8. Drake AL, Roxby AC, Ongecha-Owuor F, et al.: Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: A randomized trial. J Infect Dis 2012;205(3):366-375.
9. Roxby AC, Drake AL, Ongecha-Owuor F, et al.: Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PLoS ONE 2012;7(6):e38622.
10. Modjarrad K and Vermund SH: Effect of treating co-infections on HIV-1 viral load: A systematic review. Lancet Infect Dis 2010;10(7):455-463.
11. Barnabas RV, Webb EL, Weiss HA, and Wasserheit JN: The role of coinfections in HIV epidemic trajectory and positive prevention: A systematic review and meta-analysis. AIDS 2011;25(13):1559-1573.
12. Lisco A, Vanpouille C, Tchesnokov EP, et al.: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008;4(3):260-270.
13. Baeten JM, Lingappa J, Beck I, et al.: Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV- 2 dually infected persons. J Infect Dis 2010;203(1):117- 121.
14. Mole L, Ripich S, Margolis D, and Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176(3):766-770.
15. Zhu J, Hladik F, Woodward A, et al.: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15(8):886-892.
16. Schiffer JT, Wald A, Selke S, Corey L, and Magaret A: The kinetics of mucosal herpes simplex virus-2 infection in humans: Evidence for rapid viral-host interactions. J Infect Dis 2011;204(4):554-561.
17. Schiffer JT, Magaret A, Selke S, Corey L, and Wald A: Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother 2011;66(11):2593-2600.
18. Celum C, Wald A, Lingappa JR, et al.: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362(5):427-439.
19. Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358(15):1560- 1571.
20. Hunt PW, Martin JN, Sinclair E, et al.: Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 + T cell recovery on antiretroviral therapy. J Infect Dis 2011;203(10):1474-1483.
21. Sylwester AW, Mitchell BL, Edgar JB, et al.: Broadly targeted human cytomegalovirus-specific CD4+ and CD8 + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202(5):673-685.
22. Vanpouille C, Lisco A, Derudas M, et al.: A new class of dual-targeted antivirals: Monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis 2010;201(4):635-643.